DCAT 2022: a success for Seqens group

From March 21 to 24, 2022, a delegation representing all of the group’s pharmaceutical activities took part in the DCAT event in New York. More than a hundred meetings with customers and prospects were organized to present the Group’s new offers and future investments.

Our massive presence at this event is representative of the group’s desire to continue its development in the US, illustrated in particular by a major investment in R&D at the Devens, Massachusetts site.

As an integrated manufacturer and supplier across the entire value chain, SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty chemicals, develops and industrializes the most demanding molecules, and is constantly innovating to develop and implement the best technologies available.

 We would like to thank all of our customers, suppliers, and partners for the quality of our exchanges and for the prospects of future collaborations.